COLD + SINUS NIGHTTIME TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

PSEUDOEPHEDRINE HYDROCHLORIDE; IBUPROFEN; CHLORPHENIRAMINE MALEATE

متاح من:

VITA HEALTH PRODUCTS INC

ATC رمز:

M01AE51

INN (الاسم الدولي):

IBUPROFEN, COMBINATIONS

جرعة:

30MG; 200MG; 2MG

الشكل الصيدلاني:

TABLET

تركيب:

PSEUDOEPHEDRINE HYDROCHLORIDE 30MG; IBUPROFEN 200MG; CHLORPHENIRAMINE MALEATE 2MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

10/20/24/40/72/100

نوع الوصفة الطبية :

OTC

المجال العلاجي:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

ملخص المنتج:

Active ingredient group (AIG) number: 0349765001; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2011-06-16

خصائص المنتج

PRODUCT MONOGRAPH
COLD + SINUS DAYTIME
Ibuprofen and Pseudoephedrine Hydrochloride Tablets USP
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
Caplets
Analgesic/Antipyretic/Nasal Decongestant
COLD + SINUS NIGHTTIME
Ibuprofen 200 mg, Pseudoephedrine Hydrochloride 30 mg
and Chlorpheniramine Maleate 2 mg
Tablets
Analgesic/Antipyretic/Nasal Decongestant/Antihistamine
Vita Health Products Inc.
Date of Revision:
150 Beghin Avenue
October 19, 2020
Winnipeg, Manitoba Canada, R2J 3W2
Control # 239435
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
3
SUMMARY PRODUCT INFORMATION
..............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................................
5
ADVERSE REACTIONS
.......................................................................................................................
13
DRUG INTERACTIONS
........................................................................................................................
23
DOSAGE AND ADMINISTRATION
....................................................................................................
27
OVERDOSAGE
......................................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
..................................................................................
31
STORAGE AND STABILITY
...............................................................................................................
36
SPECIAL HANDLING INSTRUCTIONS
....................................